Search research articles
Contact Us
Filters
Showing results (41-50 of 88) with videos related to
Page
of 9
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
July 15, 1995
End of an era or not? That is the question--in response to Dr. J. M. Brown, IJROBP 32:883-885; 1995
D J Lee, K K Fu, J S Cooper, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 1, 1988
Additivity of radiosensitization by the combination of SR 2508 (etanidazole) and Ro 03-8799 (pimonidazole) in a murine tumor system
D J Honess, T H Wasserman, P Workman, et al.
American Journal of Clinical Oncology
|
August 1, 1983
Misonidazole combined with large-fraction pelvic irradiation in the treatment of patients with advanced pelvic malignancies. Preliminary report of an ongoing RTOG phase I-II study
R T Meoz, W J Spanos, L Doss, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 1, 1993
Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol
A H Russell, C Clyde, T H Wasserman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 1, 1995
EORTC Late Effects Working Group. Overview of late effects normal tissues (LENT) scoring system
P Rubin, L S Constine, L F Fajardo, et al.
Cancer
|
October 15, 1981
Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037)
T L Phillips, T H Wasserman, R J Johnson, et al.
American Journal of Clinical Oncology
|
April 2, 2004
Outcome analysis for stage IE and IIE thyroid lymphoma
Steven J DiBiase, Perry W Grigsby, Chuanfa Guo, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 30, 1995
RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system
P Rubin, L S Constine, L F Fajardo, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 18, 2008
A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02)
R E Drzymala, T H Wasserman, M Won, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 15, 1994
Radiation therapy for stage I and IIA testicular seminoma
P P Lai, M J Bernstein, H Kim, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 88) with videos related to
Sort By:
Page
of 9
International Journal of Radiation Oncology, Biology, Physics
|
July 15, 1995
End of an era or not? That is the question--in response to Dr. J. M. Brown, IJROBP 32:883-885; 1995
D J Lee, K K Fu, J S Cooper, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 1, 1988
Additivity of radiosensitization by the combination of SR 2508 (etanidazole) and Ro 03-8799 (pimonidazole) in a murine tumor system
D J Honess, T H Wasserman, P Workman, et al.
American Journal of Clinical Oncology
|
August 1, 1983
Misonidazole combined with large-fraction pelvic irradiation in the treatment of patients with advanced pelvic malignancies. Preliminary report of an ongoing RTOG phase I-II study
R T Meoz, W J Spanos, L Doss, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 1, 1993
Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol
A H Russell, C Clyde, T H Wasserman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 1, 1995
EORTC Late Effects Working Group. Overview of late effects normal tissues (LENT) scoring system
P Rubin, L S Constine, L F Fajardo, et al.
Cancer
|
October 15, 1981
Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037)
T L Phillips, T H Wasserman, R J Johnson, et al.
American Journal of Clinical Oncology
|
April 2, 2004
Outcome analysis for stage IE and IIE thyroid lymphoma
Steven J DiBiase, Perry W Grigsby, Chuanfa Guo, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 30, 1995
RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system
P Rubin, L S Constine, L F Fajardo, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 18, 2008
A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02)
R E Drzymala, T H Wasserman, M Won, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 15, 1994
Radiation therapy for stage I and IIA testicular seminoma
P P Lai, M J Bernstein, H Kim, et al.
Page
of 9